NCT06002425 Treatment Recommendations for Gastrointestinal Cancers Via Large Language Models
| NCT ID | NCT06002425 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese Academy of Sciences |
| Condition | Gastrointestinal Neoplasm Malignant |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2023-08-29 |
| Primary Completion | 2023-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2023-08-29 with a primary completion date of 2023-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will evaluate the utility of ChatGPT in recommending treatment plans for patients with gastrointestinal cancers, using both retrospective and prospective data.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years, both male and female. * Pathologically confirmed diagnosis of gastrointestinal cancer (gastric cancer or colorectal Cancer). * Detailed medical records available prior to treatment (including chief complaint, history of present illness, radiological examinations, pathological examinations, laboratory tests, etc.). * Participants will receive complete treatment in the participating hospitals. Exclusion Criteria: * Participants with cancers other than gastrointestinal cancers. * Participants who receive treatment in multiple hospitals.
Contact & Investigator
Di Dong, PhD
PRINCIPAL INVESTIGATOR
Institute of Automation, Chinese Academy of Sciences
Frequently Asked Questions
Who can join the NCT06002425 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gastrointestinal Neoplasm Malignant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06002425 currently recruiting?
Yes, NCT06002425 is actively recruiting participants. Contact the research team at di.dong@ia.ac.cn for enrollment information.
Where is the NCT06002425 trial being conducted?
This trial is being conducted at Duarte, United States, Jiangmen, China, Zhuhai, China, Zhuhai, China and 3 additional locations.
Who is sponsoring the NCT06002425 clinical trial?
NCT06002425 is sponsored by Chinese Academy of Sciences. The principal investigator is Di Dong, PhD at Institute of Automation, Chinese Academy of Sciences. The trial plans to enroll 400 participants.